All In Biotech

Free tool

FAERS Monitor: Wezlana

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761285 or its brand name (Wezlana, Ustekinumab-Auub). Reports on generic versions are filed under their own applications.

Reports

175

Serious

153

87% of reports

Hospitalization

35

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • crohn^s disease27
  • off label use25
  • colitis ulcerative21
  • inappropriate schedule of product administration19
  • drug ineffective15
  • diarrhoea14
  • psoriasis10
  • fatigue9
  • death8
  • haematochezia7
  • headache7
  • frequent bowel movements6
  • nausea6
  • therapy interrupted6
  • abdominal pain5

Reports by year received

View as table
YearReports
20246
202549
2026120

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,984 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
colitis ulcerativeSignal2156.537.81,092
frequent bowel movementsSignal626.712.2124
haematocheziaSignal715.27.480
inappropriate schedule of product administrationSignal1912.78.3194
therapy interruptedSignal610.14.641
psoriasisSignal109.25.066
off label useSignal253.42.442
diarrhoeaSignal142.61.613
abdominal pain52.61.13
fatigue91.40.71
drug ineffective151.40.81
headache71.30.60
death81.10.60
nausea60.90.40
crohn^s disease270.00.03,129,137

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.